Contract pharmaceutical manufacturer IDT Australia (ASX:IDT) has announced a 30.4 per cent increase in revenue growth for the three months ending March 2025.
AusBiotech
New Stories
-
IDT reports significant growth for the March quarter
April 29, 2025 - - Latest News -
Dimerix says FDA confirms proteinuria as acceptable endpoint for DMX-200 Phase 3 trial
April 29, 2025 - - Latest News -
Radiopharm Theranostics doses first patient in US Phase 2b imaging study of brain metastasis
April 29, 2025 - - Latest News -
Recce Pharmaceuticals enters research and development agreement with US defence
April 29, 2025 - - AusBiotech -
Atomo Diagnostics completes capital raise and undertakes restructure
April 24, 2025 - - Latest News -
Chimeric Therapeutics announces the completion of entitlement offer
April 24, 2025 - - Latest News -
Orthocell appoints its first four US Remplir distributors and expects near-term sales
April 23, 2025 - - Latest News